Across Europe, anxiety and depression remain among the most prevalent mental health conditions, affecting millions of individuals despite widespread access to psychotherapy and pharmacological treatments.

While many patients benefit from these interventions, a significant proportion continue to experience what clinicians define as treatment-resistant symptoms. These individuals often report partial relief, recurring episodes, or a persistent sense of internal disconnection that is not fully addressed by standard approaches.

This has led to a growing need to reconsider how mental health conditions are understood and treated, particularly in cases where traditional models fall short.

The Challenge of Treatment Resistance

Treatment-resistant anxiety and depression present a complex clinical challenge. Patients in this category are not necessarily unresponsive to therapy, but rather experience limited or temporary improvements that do not translate into lasting psychological change.

In many cases, these individuals have already engaged in multiple therapeutic modalities, including cognitive-behavioral therapy, medication, and mindfulness-based approaches.

Yet a recurring pattern emerges:

They develop insight into their emotional dynamics, but remain unable to shift them at a deeper level.

This gap highlights an important limitation within current treatment paradigms — the assumption that cognitive understanding alone is sufficient to produce emotional transformation.

Expanding the Therapeutic Model

Emerging perspectives in mental health suggest that more comprehensive approaches may be required — ones that engage not only cognitive processes, but also emotional, somatic, and experiential dimensions.

In this context, psychedelic-assisted therapies have gained increasing attention within European research institutions and clinical discussions.

Substances such as psilocybin, MDMA, and ayahuasca are being investigated for their ability to facilitate:

• Deep emotional processing
• Increased psychological flexibility
• Access to implicit memory and unresolved experiences
• Temporary reduction of rigid cognitive patterns

These effects may help explain their potential relevance in cases where conventional treatments have reached their limits.

The Importance of Set, Setting, and Integration

However, current evidence strongly indicates that the effectiveness of psychedelic-assisted therapy depends less on the substance itself and more on the conditions under which it is used.

The concepts of “set and setting” — referring to mindset and environment — are widely recognized as critical factors. Equally important is the integration phase, where the individual processes and applies the experience to their daily life.

Without proper structure, these experiences may remain isolated events, lacking long-term impact.

Structured Approaches in the European Context

As the field evolves, there is a noticeable shift toward structured, multi-phase therapeutic models that aim to provide a coherent framework around these experiences.

These approaches typically involve:

• Careful participant screening and preparation
• Guided sessions within a controlled and supportive environment
• Somatic and psychological support throughout the process
• Post-experience integration designed to consolidate insights into behavioral change

Within Europe, some programs offering ayahuasca retreats in Europe have begun to adopt this structured methodology, positioning the experience not as an isolated event but as part of a broader therapeutic process.

One example is the model developed by Mahanse, which organizes the experience into progressive stages — from emotional release to identity reconstruction and practical integration.

This type of framework aims to address a central issue in mental health treatment: the difficulty of translating insight into sustained transformation.

Clinical Responsibility and Ethical Considerations

Despite increasing interest, it is essential to approach psychedelic-assisted therapies with caution and clinical responsibility.

Not all individuals are suitable candidates, and careful screening is necessary to identify potential psychological or medical risks.

Furthermore, the intensity of these experiences requires appropriate professional guidance and a strong emphasis on integration.

It is also important to recognize that these approaches do not offer guaranteed outcomes. Their effectiveness depends on multiple variables, including the individual’s readiness, psychological stability, and willingness to engage in the integration process.

Conclusion

The persistence of treatment-resistant anxiety and depression suggests that current mental health models may not fully address the complexity of human emotional experience.

Psychedelic-assisted therapies represent a promising, yet still evolving, area of exploration — one that challenges traditional assumptions and opens the door to more integrative approaches.

As research continues across Europe, the focus is gradually shifting toward frameworks that combine scientific rigor with experiential depth.

Because in many cases, managing symptoms is not enough.

The real challenge lies in facilitating meaningful and lasting change.